← Back to Home

Targeting Cancer Wasting Through Neural Signals: OnVagus Device Cleared to Begin First Human Trial

Cancer cachexia is difficult to reverse with nutritional supplementation alone. OnVagus will test the safety of a transcutaneous vagal nerve blockade device in 10 patients with metastatic pancreatic cancer; whether it can stabilize weight and support continued treatment remains to be established by clinical evidence.

By SURL BioNews

For patients with advanced cancer, the challenges of treatment extend beyond the tumor to the gradual loss of weight and muscle. Cancer cachexia is a syndrome of ongoing bodily wasting that is difficult to reverse simply by increasing nutritional intake and may limit patients’ ability to tolerate chemotherapy. A neuromodulation technology preparing to enter human testing is seeking an opportunity to intervene in this process through the signals transmitted between the brain and organs.

The Terasaki Institute for Biomedical Innovation announced on October 7 that OnVagus, a medical device company incubated at the institute, had obtained institutional and regulatory clearances to begin the first human trial of its noninvasive device. The study will take place at MD Anderson Cancer Center in the United States, initially assessing safety in 10 pancreatic cancer patients with cachexia. The announcement anticipated enrollment of the first patient in October, but the information provided so far has not confirmed actual enrollment; this clearance also does not mean the device has been approved for marketing.

The device delivers electrical stimulation through the skin to modulate and block specific vagal nerve signals, without requiring surgical implantation. The vagus nerve connects the brain with organs including the liver and intestines, making it the pathway the research team has chosen for intervention. The announcement and the content republished by News-Medical state that the scientific basis comes from the preclinical study “Vagal blockade of the brain-liver axis deters cancer-associated cachexia,” published in *Cell* in 2025. As the approach moves from experimental models to patients, the next question is whether the same strategy can work safely.

Registry information displayed by Veeva and sourced from ClinicalTrials.gov further identifies the trial as NCT07700212: a Phase 1, open-label, single-arm study sponsored by MD Anderson, with planned enrollment of 10 participants and no control group. Participants must have metastatic pancreatic adenocarcinoma, have lost at least 5% of their baseline body weight since diagnosis, have experienced disease progression after first-line treatment for metastatic disease, and be receiving or preparing to receive another line of treatment. The initial results will therefore apply to this selected group of patients.

During the eight-week testing period, patients or caregivers will use the device for 30 minutes daily during the first four weeks. If it is well tolerated, use will increase to twice daily, for 30 minutes per session, during the remaining four weeks. The registry lists safety and tolerability during chemotherapy as the primary objectives, with the proportion of patients whose weight remains stable or increases as a secondary objective. The study will also explore biomarkers including CCL2, TNFα and GDF15, liver function, and survival, but these exploratory observations cannot directly be regarded as evidence of efficacy.

More comprehensive validation still depends on successful completion of this step. The institute stated that if initial safety and device use are favorable and no serious adverse events occur, the team plans to launch a one-year randomized, double-blind trial enrolling 120 participants. It would compare the active device with a sham device to assess the combined outcomes of extending time on chemotherapy and reducing weight loss from cachexia. This is a conditional follow-up plan and cannot currently be considered a study that has already begun.

The small trial now planned can first provide preliminary information on whether the device can be used safely in patients undergoing chemotherapy and whether patients and caregivers can continue operating it. Even if weight stabilization is observed, the lack of a control group will make it difficult to distinguish the device’s effects from those of other treatments or changes in the course of disease. Whether weight can be stabilized, muscle and function preserved, and patients enabled to receive treatment for longer will still need to be clarified individually in subsequent controlled trials.

References

  1. Terasaki Institute for Biomedical Innovation
  2. Veeva Clinical Trials (ClinicalTrials.gov-derived record)
  3. News-Medical